Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE in a bid to fastrack the development of a potential vaccine candidate against the novel coronavirus.Called a “rolling review," the review will allow the European Medicines Agency (EMA) to look at how the vaccine is performing in real time as data emerges from patient trials, instead of waiting for the drugmakers to submit everything at once.
BioNTech shares surged in trading before US markets opened.The start of the rolling review means that the committee has started evaluating the first batch of data on the vaccine, which come from laboratory studies (non-clinical data).